Category Health & IP

IP In Biotechnology In Need Of A New Start, Experts Say

By Catherine Saez
PARIS - Biotechnology is in dire need of a change to its business model, restoring trust among all actors and building partnerships, according to participants in a recent seminar here. After nearly thirty years, the industry still is not making profits, the field seems to be running out of steam, and controversies over patents in the health and agriculture areas have influenced public opinion, they said.

Team Of Experts Form WHO Working Group On IP And Neglected Diseases

By Kaitlin Mara The World Health Organization has released a long-awaited list of high-level experts tasked with finding innovative funding mechanisms for needed medical research on neglected diseases. The list largely contains governmental and intergovernmental representatives, and first reactions to…

Biotech, Pharma Industries To Target IP Protection Legislation, Patent Reform

By Liza Porteus Viana for Intellectual Property Watch
When the new administration and Congress come into office following the November elections in the United States, the pharmaceutical and biotechnology industries will prioritise protection of their intellectual property and innovative biological drugs as the push for cheaper, generic versions gets stronger. Patent reform also will continue to be a lobbying priority, as well as making sure intellectual property is protected in any forthcoming international trade agreements.

Green Marketers Discuss IP Protection For A Greener Market

By Kaitlin Mara
As more companies embrace environmental sustainability as an essential part of business strategy, policymakers have been questioning what they can do to create a policy environment conducive to green business. Intellectual Property Watch spoke to several green business professionals to get their view on the IP policy environments in which they work.